133 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
to receive severance benefits following termination of employment under certain conditions. The purpose of the Policy is to attract and retain qualified … .
(i)Accrued Benefits. Unless stated otherwise, where terms of this Policy are inconsistent to the terms of Executive’s Employment Agreement
8-K
ADAP
Adaptimmune Therapeutics Plc
11 Jun 24
Departure of Directors or Certain Officers
4:15pm
of healthcare benefits for a period of 12 months following such termination (formerly, nine months under the 2017 Executive Severance Policy). Our … salary for 12 months and to payment of premiums for continuation of healthcare benefits for a period of 12 months following such termination (no change
8-K
y1jcd6l8u7jl93g
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.1
x389842k eqkpsiby8
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
8-K
EX-10.2
evubydcahaste3bf
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.1
jbm2nzakjmmjsy bxj
29 Jun 23
Departure of Directors or Certain Officers
4:25pm
8-K
EX-10.2
guvghp9uuona3p
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.1
unji1h6j5qqysuy7ym
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-99.1
xkbf 8ctk7q02r32
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.3
mr26e7h5 w42x7znha
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
t446q4 9k317n0hpmj
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
425
56f1k2fer 6rs5mk
30 May 23
Business combination disclosure
4:21pm
8-K
0dofm48t3
30 May 23
Submission of Matters to a Vote of Security Holders
4:18pm